The role of androgen deprivation in the definitive management of clinically localized prostate cancer treated with radiation therapy

International Journal of Radiation Oncology Biology Physics

Volumn 43, Issue 4, 1999, Pages 707-713

  Vicini, Frank A ^a   Kini, Vijay R ^a   Spencer, William ^a   Diokno, Ananias ^a   Martinez, Alvaro A ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Androgen deprivation; Hormone therapy; Prostate neoplasms; Radiotherapy

Indexed keywords

ANDROGEN; FLUTAMIDE; GOSERELIN;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; HUMAN; MEDICAL INFORMATION; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; TREATMENT PLANNING; TUMOR LOCALIZATION;

EID: 0033058424     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(98)00513-6     Document Type: Review

References (56)

1. Vicini F., Horwitz E.M., Kini V.R., Stromberg J.S., Martinez A.A. Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate - specific antigen levels and biochemical control A comprehensive review of the literature . Int J Radiat Oncol Biol Phys. 40:1998;1101-1110.
2. Middleton R.G., Thompson I.M., Austenfeld M.S., et al. Prostate cancer clinical guidelines panel summary report on the management of clinically localized prostate cancer. J Urol. 154:1995;2144-2148.
3. Middleton R.G. The management of clinically localized prostate cancer Guidelines from the American Urological Association . CA Cancer J Clin. 46:1996;249-253.
4. Vicini F.A., Horwitz E.M., Gonzalez J., Martinez A.A. Treatment options for localized prostate cancer based upon pretreatment prostate specific antigen levels. J Urol. 158:1997;319-325.
5. Kupelian P., Katcher J., Levin H., Zippe C., Suh J., Macklis R., Klein E. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores . Cancer J Sci Am. 3:1997;78-87.
6. Fukunaga-Johnson N., Sandler H.M., McLaughlin P.W., Strawderman M.S., Grijalva K.H., Kish K.E., Lichter A.S. Results of 3D conformal radiotherapy in the management of localized prostate cancer. Int J Radiat Oncol Biol Phys. 38:1997;311-317.
7. Eastham J.A., Kattan M.W., Groshen S., Scardino P.T., Rogers E., Carlton C.E., Lerner S.P. Fifteen-year survival and recuurence rates after radiotherapy for localized prostate cancer. J Clin Oncol. 15:1997;3214-3222.
8. Shinohara K., Rhee B., Presti J.C., Carroll P.R. Cryosurgical ablation of prostate cancer Patterns of cancer recurrence . J Urol. 158:1997;2206-2210.
9. Stromberg J.S., Martinez A.A., Horwitz E.M., Gustafson G.S., Gonzalez J.A., Spencer W.F., Brabbins D.S., Dmuchowski C.F., Hollander J.B., Vicini F.A. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer Superior prostate-specific antigen response compared with external beam treatment . Cancer J Sci Am. 3:1997;346-352.
10. Ragde H., Blasko J.C., Grimm P.D., Kenny G.M., Sylvester J.E., Hoak D.C., Landin K., Cavanagh W. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinoma. Cancer. 80:1997;442-453.
11. McLeod D.G. Hormonal therapy in the treatment of carcinoma of the prostate. Cancer. 75:1995;1914-1919.
12. Garnick M.B., Fair W.R. First international conference on neoadjuvant hormonal therapy of prostate cancer Overview consensus statement . Urology. 49:(Suppl 3A):1997;1-4.
13. Iversen P. Combined androgen blockade in the treatment of advanced prostate cancer - an overview. Scand J Urol Nephrol. 31:1997;249-254.
14. Zietman A.L., Prince E.A., Nakfoor B.M., Shipley W.U. Neoadjuvant androgen suppression with radiation in the management of locally advanced adenocarcinoma of the prostate Experimental and clinical results . Urology. 49:(Suppl 3A):1997;74-83.
15. Soderdahl D.W., Wettlaufer J.N., Corn B., Gomella L.G. Neoadjuvant hormonal therapy in the management of prostate cancer A surgical and radiation therapy review . Techniques Urol. 2:1997;194-206.
16. Caubet J.F., Tosteson T.D., Dong E.W., Naylon E.M., Whiting G.W., Ernstoff M.S., Ross S.D. Maximum androgen blockade in advanced prostate cancer A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens . Urology. 49:1997;71-78.
17. Moul J.W. Contemporary hormonal management of advanced prostate cancer. Oncology. 12:1998;499-505.
18. Anderson P.R., Hanlon A.L., Movsas B., Hanks G.E. Prostate cancer patient subsets showing improved bNED control with adjuvant androgen deprivation. Int J Radiat Oncol Biol Phys. 39:1997;1025-1030.
19. Arcangeli G., Saracino B., Micheli A., D'Angelo L., Pansadoro V., Cruciani E., Marchetti P. Radiotherapy with or without androgen deprivation in the treatment of localized adenocarcinoma of the prostate. Am J Clin Oncol. 21:1998;1-5.
20. Crook J.M., Perry G.A., Robertson S., Esche B.A. Routine prostate biopsies following radiotherapy for prostate cancer Results for 226 patients . Urology. 45:1995;624-632.
21. Duchesne G.M., Bloomfield D., Wall P. Identification of intermedaite-risk prostate cancer patients treated with radical radiotherapy suitable for neoadjuvant hormone studies. Radiother Oncol. 38:1996;7-12.
22. Green N., Bodner H., Broth E., Chiang C., Garrett J., Goldstein A., Goldberg H., Gualtieri V., Gray R., Jaffe J., Kaplan R., Polse S., Ross S., Skaist L., Treible D., Vatz A., Wallack H. Improved control of bulky prostate-carcinoma with sequential estrogen and radiation therapy. Int J Radiat Oncol Biol Phys. 10:1984;971-976.
23. Neglia W.J., Hussey D.H., Johnson D.E. Megavoltage radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2:1977;873-882.
24. Pollack A., Zagars G.K., Kopplin S. Radiotherapy and androgen ablation for clinically localized high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 32:1995;13-20.
25. Spry N.A., Meffan P.M., Christie D.R.H., Morum P.E. Orchidectomy prior to definitive radiotherapy for localized prostatic cancer. Int J Radiat Oncol Biol Phys. 34:1996;1045-1053.
26. Zagars G.K., Pollack A., von Eschenbach AC. Management of unfavorable locoregional prostate carcinoma with radiation and androgen ablation. Cancer. 80:1997;764-765.
27. Zelefsky M.J., Lyass O., Fuks Z., Wolfe T., Burman C., Ling C.C., Liebel S.A. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy. J Clin Oncol. 16:1998;3380-3385.
28. Zelefsky M.J., Leibel S.A., Burman C.M., Kutcher G.J., Harrison A., Happersett L., Fuks Z. Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Biol Phys. 29:1994;755-761.
29. Zelefsky M.J., Harrison A. Neoadjuvant androgen ablation prior to radiotherapy for prostate cancer reducing the potential morbidity of therapy . Urology. 49:(Suppl 3A):1997;38-45.
30. Yang F.E., Chen G.T.Y., Ray P., Vaida F., Chiru P., Hamilton R.J., Spelbring D., Abellera M., Vijayakumar S. The potential for normal tissue dose reduction with neoadjuvant hormonal therapy in conformal treatment planning for stage C prostate cancer. Int J Radiat Oncol Biol Phys. 33:1995;1009-1017.
31. Forman J.D., Kumar R., Haas G., Montie J., Porter A.T., Mesina C.F. Neoadjuvant hormonal downsizing of localized carcinoma of the prostate Effects on the volume of normal tissue irradiation . Cancer Invest. 13:1995;8-15.
32. Shearer R.J., Davies J.H., Gelister J.S.K., Dearnaley D.P. Hormonal cytoreduction and radiotherapy for carcinoma of the prostate. Br J Urol. 69:1992;521-524.
33. Bolla M., Gonzalez D., Warde P., Dubois J.B., Mirimanoff R.O., Storme G., Bernier J., Kuten A., Sternberg C., Gil T., Collette L., Pierart M. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Eng J Med. 337:1997;295-300.
34. Pilepich M.V., Caplan R., Byhardt R.W., Lawton C.A., Gallagher M.J., Mesic J.B., Hanks G.E., Coughlin C.T., Porter A., Shipley W.U., Grignon D. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy Report of Radiation Therapy Oncology Group Protocol 85-31 . J Clin Oncol. 15:1997;1013-1021.
35. Laverdiere J., Gomez J.L., Cusan L., Suburu E.R., Diamond P., Lemay M., Candas B., Fortin A., Labrie F. Beneficial effect of combination hormonal therapy administered prior and following external beam irradiation in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.
36. Pilepich M.V., Krall J.M., Al-Sarraf M., John M.J., Doggett R.L.S., Sause W.T., Lawton C.A., Abrama R.A., Rotman M., Rubin P., Shipley W.U., Grignon D., Caplan R., Cox J.D. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma A randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-623.
37. Zagars G.K., Johnson D.E., von Eschenbach A.C., Hussey D.H. Adjuvant estrogen following radiation therapy for stage C adenocarcinoma of the prostate Long-term results of a prospective randomized study . Int J Radiat Oncol Biol Phys. 14:1988;1085-1091.
38. Pilepich M.V., Buzydlowski J.W., John M.J., Rubin P., McGowan D.G., Marcial V.A. Phase II trial of hormonal cytoreduction with megestrol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate Outcome results of RTOG 83-07 . Int J Radiat Oncol Biol Phys. 32:1995;175-180.
39. Shipley W.U. A phase III trial (RTOG 8610) comparing external-beam irradiation plus short-term maximal androgen blockade with radiation therapy for locally advanced prostate cancer. Eur Urol. 26:(Suppl 1):1994;3.
40. Pilepich M.V., Krall J.M., John M.J., Rubin P., Porter A.T., Marcial V.A., Martz K.L. Hormonal cytoreduction in locally advanced caricnoma of the prostate treated with definitive radiotherapy Preliminary results of RTOG 83-07 . Int J Radiat Oncol Biol Phys. 16:1989;813-817.
41. Pilepich M.V., John M.J., Krall J.M., McGowan D., Hwang Y.S., Perez C. Phase II Radiation Therapy Oncology Group study of hormonal cytoreduction with flutamide and zoladex in locally advanced carcinoma of the prostate treated with definitive radiotherapy. Am J Clin Oncol. 13:1990;461-464.
42. Granfors T., Modig H., Damber J., Tomic R. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement A prospective randomized study . J Urol. 159:1998;2030-2034.
43. Pilepich M.V., Krall J.M., Sause W.T., Johnson R.J., Russ H.H., Hanks G.E., Perez C.A., Zinninger M., Martz K.L. Prognostic factors in carcinoma of the prostate-analysis of RTOG study 75-06. Int J Radiat Oncol Biol Phys. 13:1987;339-349.
44. Eulau S.M., Corn B.W. Combinations of hormones and local therapies in locally advanced prostate carcinoma. Oncology. 10:1996;1193-1202.
45. Hanks G.E. Optimizing the radiation treatment and outcome of prostatic cancer. Int J Radiat Oncol Biol Phys. 11:1985;1235-1245.
46. Hellman S., Welchselbaum R.R. Androgen blockade increases progression-free survival rates for patients undergoing radiotherapy for prostate cancer. Conformal treatment reduces radiation toxicity. In mice, genetic radiotherapy can induce tumor necrosis at the molecular level. JAMA. 275:1996;1852-1853.
47. Zietman A.L., Shipley W.U. Androgen deprivation and radiation therapy prostate cancer The eveloving case for combination therapy . Int J Radiat Oncol Biol Phys. 37:1997;245-246.
48. Meyn R.E., Stephens L.C., Ang K.K., et al. Heterogeneity in the development of apoptosis in irradiated murine tumours of different histologies. Int J Radiat Oncol Biol Phys. 64:1993;583-591.
49. Stephens L.C., Hunter N.R., Ang K.K., et al. Development of apoptosis as a function of time and dose. Radiat Res. 135:1993;75-80.
50. English H.F., Kyprianou N., Issacs J.T. Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration. Prostate. 15:1989;233-250.
51. Akakura K., Bruchovsky N., Goldenberg S.L., et al. Effects of intermittent androgen suppression on androgen-dependent tumors Apoptosis and serum prostate specific antigens . Cancer. 71:1993;2782-2790.
52. D'Amico AV. What is the optimal patient selection for combined androgen ablative and radiation therapy? The role of combined modality staging. Hemat Oncol Clin N Am. 10:1996;643-651.
53. Horwitz E.M., Vicini F.A., Ziaja E.L., Gonzalez J., Dmuchowski C.F., Stromberg J.S., Brabbins D.S., Hollander J., Chen P.Y., Martinez A.A. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 36:1996;565-571.
54. Bazinet M., Zheng Wei, Begin L.R., Aprikian A.G., Karakiewicz P.I., Elhilali M.M. Morphologic changes induced by neoadjuvant androgen ablation may result in under detection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology. 49:1997;721-725.
55. Murphy W.M., Soloway M.S., Barrows G.H. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 68:1991;821-828.
56. Roach M. Neoadjuvant therapy prior to radiotherapy for clinically localized prostate cancer. Eur Urol. 32:(Suppl 3):1997;48-54.